The epidermal growth
factor receptor is a member of the ErbB family of receptors, a subfamily of
four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu
(ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR
expression or activity could result in cancer.
The epidermal growth factor receptor
(EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal
growth factor family (EGF-family) of extracellular protein ligands.
EGFR may pair with another
member of the ErbB receptor family, such as ErbB2/Her2/neu, to create an
activated heterodimer
Receptor tyrosine-protein kinase erbB-2, also known as CD340 (cluster of differentiation 340), proto-oncogene Neu, Erbb2
(rodent), or ERBB2 (human) is a protein
that in humans is encoded by the ERBB2
gene, which is also frequently called HER2 (from human
epidermal growth factor receptor 2) or HER2/neu.
The ErbB family of proteins contains four receptor
tyrosine kinases, structurally related to the epidermal growth factor receptor (EGFR), its first discovered
member. In humans, the family includes Her1 (EGFR, ErbB1), Her2 (Neu, ErbB2),
Her3 (ErbB3), and Her4 (ErbB4). The gene symbol, ErbB, is derived from the name
of a viral oncogene to which these receptors are homologous: erythroblastic
leukemia viral oncogene. Insufficient ErbB signaling in humans is associated
with the development of neurodegenerative diseases, such as multiple sclerosis
and Alzheimer's Disease, while excessive ErbB signaling is associated with the
development of a wide variety of types of solid tumor.